Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct Problems
Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
It is hypothesized that, when given at the lowest effective dose, the favorable side effect
profile combined with it's lower propensity for weight gain would make SPN-810 a candidate
for treatment of persistent serious conduct problems in pediatric subjects with ADHD.